Stereotactic radiotherapy is a highly conformal treatment option for intracranial and extracra- nial malignancies. Stereotactic radiotherapy utilizes specialized equipment specifically designed to avoid normal tissue while delivering ablative treatments with submillimeter precision and accu- racy. Linear accelerator based stereotactic radiotherapy incorporates on-board image guidance utilizing cone beam computed tomography (CT). Many institutions lack the ability to provide image guidance with cone beam CT but delivery of highly conformal treatments with submillimeter pre- cision and accuracy is still feasible. The purpose of this retrospective, pilot study was to describe clinical outcomes for a group of dogs with neurological disease that were treated with an stereo- tactic radiotherapy technique utilizing intensity modulated radiation therapy, megavoltage com- puted portal radiography, a bite plate, thermoplastic mold, and mask based positioning system. Twelve dogs with neurological clinical signs were included. The diagnosis of intracranial tumor was made based on advanced imaging (12/12) and confirmed via histopathology (3/12). Twelve cou- rses of stereotactic radiotherapy, utilizing three fractions of 8.0 Gy, were delivered on alternat- ing days. Self-resolving neurological deterioration was observed in two patients during stereotac- tic radiotherapy. Neurological progression free interval and median survival time were 273 days (range: 16–692 days) and 361 days (range: 25–862 days). Stereotactic radiotherapy using com- puted portal radiography may be a safe treatment option for dogs with intracranial tumors.